VIR•benzinga•
Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why
Summary
Vir Biotechnology's Phase 1 data highlights early promise for T-cell engagers targeting HER2-positive tumors and prostate cancer with manageable safety.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 10, 2025 by benzinga